Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins. The sequence and structure of these naturally supercharged human proteins enable biologic drugs to penetrate and function inside of mammalian cells. This new class of proteins is the foundation of Permeon Biologics' novel Intraphilin Technology Platform and provides an innovative approach to develop intracellular protein biologic drugs, such as intracellular monoclonal antibodies and enzyme replacement therapies. Intraphilins enable functional proteins to act inside cells to treat disease, impacting over 1,500 intracellular target proteins currently considered undruggable with available technologies.
The data were published online today in the journal Chemistry & Biology in a seminal paper by David R. Liu, Ph.D., professor of chemistry and chemical biology at Harvard University and investigator at the Howard Hughes Medical Institute, and his colleagues. The findings represent natural scaffolds for developing potent human intracellular biologic drugs, and also raise the possibility that some of these supercharged proteins may penetrate cells as part of their native biological functions. The ability of human Intraphilins to penetrate cells to enable intracellular protein biologics has not been previously reported.
"The data show that naturally supercharged Intraphilin proteins already exist within the human body and can enable the delivery of protein biologics into mammalian cells in vivo," said Dr. Liu, Permeon's scientific founder and scientific advisory board chairman. "Intraphilins are now being developed as a new class of human protein therapeutics to access previously undruggable intracellular target proteins and pathways."
The study sought to determine if this class of proteins could provide
|Contact: Michele Rozen|
Pure Communications Inc.